 - Current diagnosis of an immune disease which by itself or its treatment could impair the safety andor efficacy evaluation of Roledumab in this study. These diseases are: All immune deficiencies, particularly those requiring IV-Ig supplementation or other systemic treatment connective tissue and autoimmune diseases e.g., systemic lupus erythematosus, antiphospholipid syndrome, Sjögrens syndrome, rheumatoid arthritis, ankylosing spondylarthritis requiring systemic immunosuppressive treatment allergic and inflammatory diseases requiring systemic immunosuppressive treatment. 